Trials / Completed
CompletedNCT04605666
CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies
CD19-Chimeric Antigen Receptor-T2 Cells for CD19 Positive Relapsed/Refractory B Cell Leukemia/Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Chimeric antigen receptor T cells (CAR-T cells) has been recognized a promising treatment option for treating B cell derived malignancy. The purpose of this study is to evaluate the efficacy and safety of third-generation anti-CD19 CAR T-cells (CD19-CAR-T2 Cells) in patients with CD19+ relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell Non Hodgkin Lymphoma (B-NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CD19-CAR-T2 Cells | CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0. |
Timeline
- Start date
- 2020-05-01
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
- First posted
- 2020-10-28
- Last updated
- 2024-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04605666. Inclusion in this directory is not an endorsement.